SCHEMBL7400722

SCHEMBL7400722

CC(C)(C)OC(=O)NCCCOc1cc(N(C=O)CC(NC(=O)OCc2ccccc2)C(=O)O)on1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.47
MAPT P10636 3/20 0.47
ITGB3 P05106 2/20 0.44
ITGA2B P08514 2/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.44
KLK7 P49862 2/20 0.43
KLK5 Q9Y337 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
RECQL P46063 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
CAPN1 P07384 1/20 0.40
CAPN2 P17655 1/20 0.40
PPARA Q07869 1/20 0.40
PAX8 Q06710 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL7403599 0.83 ITGB3 (0.49) ITGB3ITGA2B
SCHEMBL7400723 0.83 SYK (0.50) SYKMAPTITGB3ITGA2BPOLB
SCHEMBL7405166 0.82 ITGB3 (0.48) ITGB3ITGA2B
SCHEMBL7406992 0.79 SYK (0.49) SYKMAPTITGB3ITGA2BPOLB
SCHEMBL8647208 0.77 SYK (0.47) SYKMAPTITGB3ITGA2BPOLB
SCHEMBL8647590 0.75 MAPT (0.44) SYKMAPTITGB3ITGA2BPOLB
SCHEMBL918813 0.75 SYK (0.60) SYKMAPTITGB3ITGA2BKLK7
SCHEMBL1021938 0.75 SYK (0.60) SYKMAPTITGB3ITGA2BKLK7
SCHEMBL4958981 0.75 SYK (0.60) SYKMAPTITGB3ITGA2BKLK7
SCHEMBL7401916 0.74 ITGB3 (0.37) ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996037492-A1 ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-11-28 WO disclosed